3K3A-APC demonstrates safety in clinical trial for acute ischemic stroke
A preliminary Phase 2 clinical trial has demonstrated that patients…
A preliminary Phase 2 clinical trial has demonstrated that patients with acute ischemic stroke, can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug...